Medication, which has already received FDA approval, represents an alternative to daily treatment with tablets, which can facilitate patients’ adherence to treatment
It has announced the recommendation of injectable Lenacapavir, which can be administered every six months, such as a new Pre-Exposition Prophylaxis option (PREP) for HIV prevention. This medication, which has already been approved by the FDA, represents an alternative to daily treatment with tablets, which can facilitate patients’ adherence to treatment. Tedros Adhanom Ghebreyesus, WHO Director General, emphasized that despite the uncertainty around the development of a HIV vaccine, Lenacapavir proves to be an effective solution. Clinical studies indicate that the drug can prevent almost all infections by the virus, offering new hope in combating the epidemic.
The new guidelines were presented during the 13th Conference of the International AIDS Society on HIV Science, held in Kigali, Rwanda. It is important to emphasize that Lenacapavir is not a vaccine, but an antiviral that acts by blocking replica. WHO is committed to ensuring that this innovation quickly reaches the communities they need most, expanding available prevention options. With the introduction of Lenacapavir, more people are expected to have access to effective HIV protection methods, contributing to the reduction of infection rates.
Posted by Sarah Paula
*Report produced with the aid of AI
